Veracyte Says Data Supporting Use of Percepta Bronchial Genomic Classifier to Be Presented at CHEST 2015

Veracyte, Inc. VCYT announced that data assessing the clinical utility and performance of the company's genomic test to improve lung cancer diagnosis will be presented at the CHEST 2015 Annual Meeting, being held October 24-28 in Montreal, Canada. Data from the first study suggest the ability of the Percepta Bronchial Genomic Classifier to reduce unnecessary, invasive and costly diagnostic procedures following inconclusive bronchoscopy results among patients being evaluated for potentially cancerous lung nodules or lesions. The second abstract reviews the AEGIS I and II studies, which validated the Percepta test's ability to identify patients who are at low risk of malignancy following an inconclusive bronchoscopy. "Diagnostic ambiguity in lung cancer and the invasive, risky and costly procedures that often result put tremendous strain on patients, medical professionals and the healthcare system. This challenge becomes even more pronounced as millions of Americans at high risk of lung cancer have recently become eligible for annual CT screening," said Bonnie Anderson, president and chief executive officer of Veracyte. "We are extremely pleased to further build the evidence supporting the use of the Percepta test See full press release